CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)-Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) by Schmidt-Hieber, M. et al.
Annals of Oncology 27: 1207–1225, 2016
doi:10.1093/annonc/mdw155
Published online 6 April 2016
CNS infections in patients with hematological disorders
(including allogeneic stem-cell transplantation)—
Guidelines of the Infectious Diseases Working Party
(AGIHO) of the German Society of Hematology and
Medical Oncology (DGHO)
M. Schmidt-Hieber1*, G. Silling2, E. Schalk3, W. Heinz4, J. Panse2, O. Penack5, M. Christopeit6,
D. Buchheidt7, U. Meyding-Lamadé8,9,10, S. Hähnel11, H. H. Wolf12, M. Ruhnke13, S. Schwartz14 &
G. Maschmeyer15
1Department of Hematology, Oncology and Tumor Immunology, HELIOS Clinic Berlin-Buch, Berlin; 2Department of Hematology, Oncology and Stem Cell Transplantation,
University Hospital, Aachen, Medical Faculty, RWTH Aachen, Aachen; 3Department of Hematology and Oncology, Otto-von-Guericke University Hospital Magdeburg,
Magdeburg; 4Department of Internal Medicine II, University Hospital Würzburg, Center of Internal Medicine, Würzburg; 5Department of Hematology, Oncology and Tumor
Immunology, Charité University Medicine, Campus Virchow Clinic, Berlin; 6Department of Stem Cell Transplantation, University Medical Center Hamburg Eppendorf,
Hamburg; 7Department of Hematology and Oncology, Mannheim University Hospital, University of Heidelberg, Mannheim; 8Department of Neurology, Hospital Nordwest
Frankfurt, Frankfurt/M., Germany; 9Brunei Neuroscience Stroke and Rehabilitation Centre, Jerudong, Brunei Darussalam; 10Department of Neuroinfectiology, Otto-
Meyerhof-Centre, University of Heidelberg, Heidelberg; 11Department of Neuroradiology, University Hospital Heidelberg, Heidelberg; 12Department of Hematology and
Oncology, University Hospital Halle, Halle; 13Paracelsus Clinic Osnabrück, Osnabrück; 14Department of Hematology and Oncology, Charité University Medicine, Campus
Benjamin Franklin, Berlin; 15Department of Hematology, Oncology and Palliative Care, Ernst von Bergmann Clinic, Potsdam, Germany
Received 3 December 2015; revised 21 March 2016; accepted 24 March 2016
Infections of the central nervous system (CNS) are infrequently diagnosed in immunocompetent patients, but they do
occur in a significant proportion of patients with hematological disorders. In particular, patients undergoing allogeneic
hematopoietic stem-cell transplantation carry a high risk for CNS infections of up to 15%. Fungi and Toxoplasma gondii
are the predominant causative agents. The diagnosis of CNS infections is based on neuroimaging, cerebrospinal fluid
examination and biopsy of suspicious lesions in selected patients. However, identification of CNS infections in immuno-
compromised patients could represent a major challenge since metabolic disturbances, side-effects of antineoplastic or
immunosuppressive drugs and CNS involvement of the underlying hematological disorder may mimic symptoms of a
CNS infection. The prognosis of CNS infections is generally poor in these patients, albeit the introduction of novel sub-
stances (e.g. voriconazole) has improved the outcome in distinct patient subgroups. This guideline has been developed
by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
with the contribution of a panel of 14 experts certified in internal medicine, hematology/oncology, infectious diseases,
intensive care, neurology and neuroradiology. Grades of recommendation and levels of evidence were categorized by
using novel criteria, as recently published by the European Society of Clinical Microbiology and Infectious Diseases.
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introduction
Infections of the central nervous system (CNS) occur in a relevant
proportion of immunocompromised patients and contribute
significantly to morbidity and mortality. Only limited data are
available on the clinical characteristics, optimal diagnostic proce-
dures and treatment of CNS infections in these patients, and
studies on CNS infections frequently focused on specific causative
agents or distinct patient subgroups such as recipients of allogen-
eic hematopoietic stem-cell transplantation (allo-HSCT) [1, 2].
This guideline focuses on patients with hematological malig-
nancies including allo-HSCT recipients defined as ‘patients with
hematological disorders’ hereafter. Patients with nonmalignant
hematological disorders (e.g. aplastic anemia) or solid tumors
are not specifically excluded albeit CNS infections are very rare
in these patients and larger analyses focusing on CNS infections
in these subgroups are lacking. In the first part of this guideline,
an overview on epidemiology, causative agents, risk factors,
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pathogenesis, prophylaxis in addition to general diagnostic strat-
egies and management of CNS infections is given. The second
part focuses on distinct infectious agents. For recommendations
on diagnosis and treatment of bacterial CNS infections (including
tuberculous meningitis), see supplementary Material, available at
Annals of Oncology online. The strengths of recommendation and
levels of evidence were categorized according to the European
Society of Clinical Microbiology and Infectious Diseases (ESCMID)
criteria (Table 1) [3].
consensus process
See supplementary Material, available at Annals of Oncology
online.
epidemiology and causative agents
Patients undergoing allo-HSCT are among those with the
highest risk for CNS infections with an overall incidence of up
to 15% [1, 4, 5]. Aspergillus and Toxoplasma spp. are frequently
prevailing in these patients [4, 6]. Patients after an alemtuzu-
mab-based conditioning before allo-HSCT carry a considerable
risk for viral CNS infections [2, 7]. Mucormycosis is diagnosed
in ∼0.1% of all patients with hematological disorders, but an
increased incidence (1.0%–1.9%) has been reported among
patients with acute myeloid leukemia [8]. The lungs are fre-
quently infected in mucormycosis, but the CNS might be
involved in 10%–20% of patients [9, 10]. Progressive multifocal
leukencephalopathy (PML) is a rare (<1%), but frequently fatal
CNS disease caused by the JC virus. It mainly affects allo-HSCT
recipients, but also patients after rituximab-based treatment
strategies or with multiple lines of immunosuppression [2, 11,
12]. Bacterial CNS infections are rarely diagnosed in patients
with hematological disorders, and they occur more frequently in
patients with intraventricular devices or after neurosurgical
interventions [1, 13–15].
pathogenesis
See supplementary Material, available at Annals of Oncology
online.
prophylaxis
Prophylactic strategies should follow recommendations for im-
munocompromised patients as published elsewhere [16, 17].
Patients with hematological disorders requiring intracerebral
devices such as an external ventricular drainage could benefit
from antimicrobial-impregnated catheters since they might be
associated with a lower infection rate in comparison to standard
catheters [15].
general strategies to diagnose and
to treat CNS infections in patients
with hematological disorders
Some principal aspects regarding the management of CNS
infections in patients with hematological disorders should be
considered:
(i) The management of CNS infections in patients with hema-
tological disorders requires a high level of awareness, as
neurological symptoms could be nonspecific and caused
by noninfectious conditions related to the underlying
disease and/or side-effects of antineoplastic or immuno-
suppressive treatment [1, 5, 14].
(ii) While clinical presentations of CNS infections in immuno-
competent hosts are broadly categorized into meningitis,
meningoencephalitis, cerebritis/abscess formation and in-
fection of intracerebral devices, diminished inflammatory
responses in immunocompromised patients can lead to
only subtle symptoms. Mass lesions can be blurred by
rather nonspecific cerebral dysfunctions such as confusion
or altered consciousness [1, 14].
Table 1. Strength of recommendation (A) and quality of evidence (B) [3]
(A)
Grade Strength of recommendation
Grade A AGIHO ‘strongly’ supports a recommendation for use
Grade B AGIHO ‘moderately’ supports a recommendation for use
Grade C AGIHO ‘marginally’ supports a recommendation for use
Grade D AGIHO ‘supports’ a recommendation ‘against’ use
(B)
Level Quality of evidence
I Evidence from at least one properly designed randomized, controlled trial
II* Evidence from at least one well-designed clinical trial, without randomization; from cohort or case-controlled analytic studies (preferably from
>1 center); from multiple time series; or from dramatic results of uncontrolled experiments
*: Added index
r: Meta-analysis or systematic review of randomized, controlled trials
t: Transferred evidence, that is, results from different patients’ cohorts, or similar immune-status situation
h: Comparator group is a historical control
u: Uncontrolled trial
a: Published abstract (presented at an International Symposium or meeting)
III Evidence from opinions of respected authorities, based on clinical experience, descriptive case studies
Quality of evidence is used for treatment recommendations only (and not for diagnostic procedures).
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(iii) Defined patient groups predispose for infections with
certain pathogens based on their pattern of immunosup-
pression (defects in cell-mediated immunity versus defect-
ive humoral immunity) [18, 19]. Bacterial, fungal and viral
CNS infections typically occur in neutropenic patients.
Defects in T-cell immunity or in function of macrophages
predispose for cerebral toxoplasmosis and cryptococcal
meningitis [2, 18, 20].
(iv) Variations in the frequency of causative organisms (e.g.
Toxoplasma spp. Histoplasma capsulatum, Mycobacterium
tuberculosis) due to regional endemic differences should be
taken into account [21–23].
diagnosis
Any suspicion of CNS infection should immediately trigger ad-
equate diagnostic procedures including neuroimaging, cerebro-
spinal fluid (CSF) examination and, in selected cases, biopsy of
focal lesions (Figure 1). CSF analyses including various methods
such as staining and microscopy, culturing, serological techniques
and PCR assays are crucial to diagnose meningoencephalitis
which is typically caused by viruses, Candida spp., bacteria or
more rarely Cryptococcus spp. (Figure 1, Table 2). For these CNS
infections, brain biopsy is required only in selected cases. Focal
lesions, typically caused by Toxoplasma or Aspergillus spp. are
commonly diagnosed by histopathology of suspicious lesions.
Histopathological work-up should be done using adequate stain-
ing methods such as Calcofluor white. Routine parameters in the
CSF are frequently nonspecifically altered in these patients.
Neuroimaging should commonly be based on magnetic res-
onance imaging (MRI) since it is more sensitive than computed
tomography (CT) scan for diagnosis of the majority of CNS
infections [102–105].
Further diagnostic methods such as positron emission tomog-
raphy might help in selected patients to differentiate infectious
from noninfectious CNS lesions [106].
antimicrobial treatment
Given the dismal outcome of delayed treatment in patients with
hematological disorders and CNS infection, antimicrobial treat-
ment should be initiated promptly once collection of CSF and
blood cultures has been completed (Figure 1) [107–109]. After
isolation and in vitro susceptibility testing of a (potentially)
causative pathogen, antimicrobial treatment should be modified
accordingly. Recommendations for empiric, pre-emptive and
targeted treatment are specified in Figure 1, Table 3 and supple-
mentary Table S1, available at Annals of Oncology online.
Clinical symptoms indicative of CNS infection
(e.g. paresis, fever, signs of meningitis)
Neuroimaging (MRI and/or
CT scan) showing focal,
parenchymatous
abnormalities (e.g. brain
abscess)
Imaging of the neurocranium: MRI (if readily
available), otherwise CT scan (usually followed by
MRI as soon as possible)
Neuroimaging (MRI and/or
CT scan) showing no focal
abnormalities
Criteria for sterotactic brain
biopsy/neurosurgical resection
of brain lesions not fulfilled*
Might be considered in
addition to stereotactic
biopsy in selected cases
Analysis of CSF including cell count,
cell differentiation, gram staining,
measurement of glucose, LDH and
protein concentration, cultures (e.g.
bacterial and fungal) and PCR
analyses (e.g. herpes viruses
detection) (specified in Table 2)
Empirical/preemptive treatment:
Imaging results and CSF analyses indicative of:
• Bacterial CNS infection (e.g. abscess and/or neutrophil
pleocytosis): 3rd generation cephalosporin or meropenem +
ampicillin +/– vancomycin
• Fungal CNS infection (e.g. abscess or infarction): voriconazole
• Cerebral toxoplasmosis (e.g. ring enhancement): pyrimethamine
+ sulfadiazine
Directed treatment:
Should be initiated immediately after isolation of a (potential) causative organism and follow the recommendations specified in
Table 3
Empirical/preemptive treatment:
3rd generation cephalosporin or
meropenem + ampicillin +/–
vancomycin +/– acyclovir (if viral
encephalitis is suspected)
Stereotactic brain
biopsy/neurosurgical resection
of brain lesions (if technically
possible) followed by
identification and resistance
testing of potential causative
organisms
*The decision on brain biopsy/neurosurgical resection should always be made on the basis of the technical feasibility, the suspicious
causative agent, and other factors (such as presence of thrombocytopenia). For example, brain biopsy might not be required to
establish the diagnosis of PML in patients with typical neuroimaging findings together with a positive CSF JC virus PCR.
Figure 1. Diagnostic procedures and management in patients with hematological disorder and CNS infection.
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Table 2. Recommendations to diagnose CNS infections in patients with hematological disorders
Intention Intervention SoR Comments References
Toxoplasma spp.
To diagnose cerebral toxoplasmosis Demonstration of tachyzoites and/or cysts after
Wright-Giemsa and/or immuno-peroxidase
staining (CSF or biopsy material)
A Can be combined with isolation of the parasite, e.g. after mouse inoculation
or inoculation in tissue cell cultures
[24]
PCR (CSF) B Sensitivity 50%–100%, specificity 90%–100%. Should be performed within
the first week after initiation of antitoxoplasmic treatment
[25–28]
IgG-ELISA/LAT (CSF) C IgG-ELISA is more sensitive than LAT (92% versus 48%) [29]
IgM-ELISA (CSF) D Negligible value [29]
LAMP assay (CSF) D Few data [25]
Fungi
To detect and specify a fungus obtained
from CNS biopsy
Paraffin sections of CNS biopsies (e.g. using H&E,
PAS, or Grocott/silver stains)
A Might not always be possible (e.g. in patients with thrombocytopenia). Thus,
biopsy of lesions from anatomic sites other than CNS might be considered
sufficient to establish the diagnosis
[30, 31]
To diagnose CNS aspergillosis Detection of galactomannan (CSF) B No validated cutoff (probably lower than for serum samples), reduced
sensitivity under antifungal treatment
[32–36]
PCR (CSF) B Sensitivity and specificity 90%–100% (in-house assays) [33, 37–41]
Fungal cultures (CSF) B Positive in ∼30% of patients with Aspergillusmeningitis [32, 36]
Detection of (1→3)-β-D-glucan (CSF) C Few data [42, 43]
To diagnose Candida CNS infection Microscopy/culture (CSF) A Sensitivity of microscopy ∼40%, of culture 40%–80% [44, 45]
CNS biopsy (culture/histopathology) B If biopsy can be achieved (e.g. using Grocott/silver stains) [44, 45]
Detection of Candidamannan antigen (CSF) C Few data [46–48]
Detection of (1→3)-β-D-Glucan (CSF) C [43, 49]
PCR (CSF) C [38, 50–52]
To diagnose mucormycosis CNS/extracerebral tissue biopsy (culture/
histopathology)
A Useful stains: PAS, Grocott/silver stains, Calcofluor white [53]
PCR (tissue) B Few data [54–56]
PCR (blood) C [57]
CSF-based diagnostics D No valid data
To diagnose cryptococcal meningitis Culture (CSF) A Sensitivity 60%–100%, specificity near 100% [58–61]
CSF microscopy (e.g. after India Ink staining) A Sensitivity 70%–95%, specificity near 100%; often operator-dependent [58, 59, 61, 62]
Detection of capsular antigen, e.g. by EIA, LAT or
LFA (CSF)
A Sensitivity and specificity 90%–100% [58, 60, 61, 63]
(Nested) PCR (CSF) B Sensitivity and specificity near 100% [58–61]
Biopsy (culture/histopathology), e.g. after Grocott/
silver or Alcian blue staining
C Required only in selected cases [60]
Viruses
To diagnose HSV encephalitis PCR (CSF) A Sensitivity and specificity 95%–100% [64, 65]
Detection of HSV antigens and antibodies (CSF) C Sensitivity and specificity of HSV antigen detection ∼90%, frequently
nonspecific antibodies
[66, 67]
Culture (CSF) D Low sensitivity of culture might be due to inhibiting HSV IgG antibodies [66, 68, 69]
To diagnose CMV CNS disease PCR (CSF) A Sensitivity nearly 100% [70–72]
Culture (CSF) C Might only be used as an adjunctive test (sensitivity ∼20%) [69, 72]
To diagnose EBV meningoencephalitis PCR (CSF) A Might be false-negative in allo-HSCT recipients [2, 73–76]
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To diagnose HHV-6 meningoencephalitis PCR (CSF) A Might be positive in allo-HSCT recipients without associated symptoms [77–79]
To diagnose VZV CNS disease PCR (CSF) A [80–82]
Detection of VZV IgG antibodies (CSF) B Might be more sensitive than CSF VZV PCR in the case of cerebral VZV
vasculopathy
[83–85]
To diagnose JC virus-related PML Biopsy of CNS lesions A Required for definitive diagnosis, demonstration of the typical triad including
demyelination, bizarre astrocytes and enlarged oligodendroglial nuclei
[86, 87]
PCR (CSF) A Sensitivity 75%–100%, repetitive CSF analyses might be useful, might also be
false-positive (e.g. in healthy individuals with JC virus viremia)
[86, 88–90]
Bacteria
To identify pathogen and perform
resistance testing
Culture (CSF) A CSF culture yield might significantly be reduced in patients with delayed
lumbar puncture (>4 h) after initiation of antibiotic treatment
[91–93]
Culture (blood) A Positive in 50%–80% of patients, after initiation of antibiotic treatment in
∼20%
[92, 94]
To identify bacteria in culture-negative
CSF specimens
Gram stain (CSF) A Sensitivity 30%–93%, specificity 97% (frequently still positive after initiation
of antibiotic treatment)
[91, 94, 95]
To document bacterial
meningoencephalitis versus
meningoencephalitis of other origin
Counting and differentiation of CSF cells A Might be of inferior value in neutropenia or after initiation of antibiotic
treatment
[14, 92, 96, 97]
Determination of CSF LDH concentration B [98]
Determination of CSF protein and glucose
concentration
C [14, 92, 96, 97]
To identify causative bacterial agent in
meningoencephalitis
CSF PCR B [99–101]
SoR, strength of recommendation; ELISA, enzyme-linked immunosorbent assay; LAT, latex agglutination test; LDH, lactate dehydrogenase; LAMP, loop-mediated isothermal amplification; H&E, hematoxylin
and eosin; PAS, periodic acid-Schiff; EIA, enzyme immunoassay; LFA, lateral flow immunochromatographic assay.
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Table 3. Recommendations to treat CNS infections in patients with hematological disordersa
Causative agent Intention Intervention SoR/QoE Comments References
Toxoplasma spp.
Toxoplasma spp. Primary anti-infective
treatment and
prevention of CNS
relapse
- to cure -
Pyrimethamine (orally, 100–200 mg load, then
50 mg/day) + sulfadiazine (orally, 1 g q6h)
AIIt Anti-infective agents should be given for ∼6 weeks in
indicated dosages, then as maintenance therapy half
of the original dosage for at least 3 months
Pyrimethamine should be combined with folinic acid
[110]
Pyrimethamine (orally, 100–200 mg load, then
50 mg/day) + clindamycin (orally or i.v., 600
mg q6h)
BIIt [111–113]
Trimethoprim (10 mg/kg/day)—
sulfamethoxazole (orally or i.v.)
BIIt [114]
Atovaquone (orally, e.g. 750 mg q6h) BIIt,u Might be used for maintenance in patients intolerant to
conventional antitoxoplasmic agents, could be
combined as primary treatment with pyrimethamine
or sulfadiazine
[115, 116]
Fungi
Aspergillus spp. Primary anti-infective
treatmentb
- to cure -
Voriconazole (i.v., 6 mg/kg q12h for the first
24 h, then 4 mg/kg q12h)
AIIu [117, 118]
-To obtain material
for diagnosis
L-AmB (i.v., ≥5 mg/kg/day, optimal dose
unclear) or ABLCc (i.v., 5 mg/kg/day)
BIII Reserved for rare cases (e.g. severe intolerance to
voriconazole, resistant isolates), might in particular be
useful if mucormycosis cannot be excluded
[119–126]
-To prevent serious
neurological
sequelae, decrease
the burden of
infected tissue and
improve outcome
Itraconazole DIII Higher doses (800 mg/day) might be beneficial, low CNS
penetration
[127–129]
Caspofungin, micafungin DIII Few clinical data [130, 131]
Posaconazole DIII [132, 133]
D-AmB DIIu Unfavorable toxicity profile, low efficacy [134, 135]
Stereotactic or open craniotomy for biopsy,
abscess drainage or excision of lesions
BIIu Resection might be effective in particular in patients with
a focal lesion, a combined neuro- and rhinosurgical
approach is recommended in selected cases
[117–119, 136–139]
Candida spp. Primary anti-infective
treatmentb
- to cure -
L-AmB (i.v., ≥5 mg/kg/day, optimal dose
unclear) or ABLCc (i.v., 5 mg/kg/day) ±
5-FC (i.v., 25 mg/kg q6h)d
BIII Mainly preclinical data, case reports or small patient
series (and data from extracerebral systemic Candida
infection)
[140–144]
Voriconazole (i.v., 6 mg/kg q12h for the first
24 h, then 4 mg/kg q12h)
CIII [145, 146]
Fluconazole (i.v., loading dose 800 mg/day,
then 400 mg/day)
CIII If a susceptible Candida spp. has been isolated and the
patient is clinically stable and not neutropenic and
had no prior azole exposure
[44, 141, 147–149]
D-AmB DIII Unfavorable toxicity profile [44, 135, 147, 149, 150]
Caspofungin, micafungin, anidulafungin DIII Mainly preclinical data and few case reports [151–153]
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Mucorales Primary treatment
- to cure -
Surgery AIIt,u Should be considered whenever possible [8, 9, 154, 155]
L-AmB (i.v., ≥5 mg/kg/day, optimal dose
unclear, up to 10 mg/kg/day has been used)
AIIt,u Treatment delay may enhance mortality, response rate
80%–95%
[10, 155, 156]
Reduction of immunosuppression BIII No comparative data, not always feasible
ABLCc (i.v., 5 mg/kg/day) BIII Around 70% response rate [157]
L-AmB (i.v., ≥5 mg/kg/day) + caspofungin
(i.v., 50–70 mg/day)
CIII [158–163]
Posaconazole (preferable i.v., 300 mg q12h for
the first 24 h, then 300 mg/day)
CIII Low CNS penetration, dosages up to 3200 mg/day have
been used
[156, 164]
Posaconazole (preferable i.v., 300 mg q12h for
the first 24 h, then 300 mg/day) +
L-AmB (i.v., ≥5 mg/kg/day)
CIII Might be used for extended cases or patients refractory
to single-agent treatment
[156, 161, 164–166]
Itraconazole (orally or i.v., higher dosages of up
to 800 mg/day might be used)
CIII Low CNS penetration [9]
D-AmB DIII Unfavorable toxicity profile [9, 135]
Salvage treatment
- to cure/prolong
survival -
Posaconazole (preferable i.v., 300 mg q12h for
the first 24 h, then 300 mg/day)
BIII Might be combined with caspofungin or L-AmB [164, 167, 168]
Isavuconazole (i.v. or orally, 200 mg q8h for the
first 48 h, then 200 mg/day)
CIII [169, 170]
Cryptococcus spp. Primary treatment
- to cure -
L-AmB (i.v., 3–4 mg/kg/day) or ABLCc (i.v., 5
mg/kg/day) + 5-FC (i.v., 25 mg/kg q6h)d
AIIt • Induction therapy for at least 4 weeks, might be
followed by consolidation with fluconazole (400 mg/d)
at least 8 weeks
• Consider unfavorable toxicity profile of D-AmB
[171–173]
D-AmB (i.v., 0.7–1.0 mg/kg/day) + 5-FC (i.v.,
25 mg/kg q6h)d
BIIt [171–174]
D-AmB (i.v., 0.7–1.0 mg/kg/
day) + voriconazole (preferable i.v., 6 mg/kg
q12h for the first 24 h, then 4 mg/kg q12h)
BIIt [175]
L-AmB (i.v., 3 mg/kg/day) BIIt [176–178]
D-AmB (i.v., 0.7–1.0 mg/kg/day) + fluconazole
(preferable i.v., 800–1200 mg/day)
CIIt [171, 173, 175, 179]
Voriconazole (preferable i.v., 6 mg/kg q12h for
the first 24 h, then 4 mg/kg q12h)
CIII [180]
ABLCc (i.v., 5 mg/kg/day) CIII [181]
Fluconazole (preferable i.v., loading dose 1200
mg/day, then 800 mg/day) + 5-FC (i.v., 25
mg/kg q6h)d
CIIt Study performed in Malawi with limited economic
resources
[182]
Salvage treatment
- to cure/prolong
survival -
Voriconazole (preferable i.v., 6 mg/kg q12h for
the first 24 h, then 4 mg/kg q12h)
CIII Clinical efficacy rate ∼40% [183]
Posaconazole (preferable i.v., 300 mg q12h for
the first 24 h, then 300 mg/day)
CIII Clinical efficacy rate ∼50% [132]
Primary or salvage
treatment
Caspofungin, micafungin, anidulafungin DIII No relevant activity [184]
Viruses
Continued
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Table 3. Continued
Causative agent Intention Intervention SoR/QoE Comments References
HSV Primary or salvage
treatment
- to cure -
Aciclovir (i.v., 10 mg/kg q8h) AIIt Treatment duration at least 2–3 weeks
e [2, 73, 185–189]
Foscarnet (i.v., 60 mg/kg q8h or 90 mg/kg
q12h)
CIII Might be used in refractory cases [190]
Valaciclovir (orally, 1 g q8h) CIII Might be used as continuation therapy [191–194]
CMV Primary or salvage
treatment
- to cure -
Ganciclovir (i.v., 5 mg/kg q12h) or foscarnet
(i.v., 60 mg/kg q8h or 90 mg/kg q12h) as
single agent
AIII Consider main side-effects (myelotoxicity versus
nephrotoxicity) and the presence of CMV resistance
mutations (e.g. UL97, UL54)
[188]
Ganciclovir (i.v., 5 mg/kg q12h) + foscarnet
(i.v., 60 mg/kg q8h or 90 mg/kg q12h)
BIII [188, 195–197]
Cidofovir (i.v., optimal dosage unclear, e.g.
5 mg/kg once weekly)
CIII [198, 199]
Ganciclovir (i.v., 5 mg/kg q12h) + cidofovir
(i.v., e.g. 5 mg/kg once weekly)
CIII [195, 200]
Foscarnet (i.v., 60 mg q8h or 90 mg/kg
q12h) + cidofovir (i.v., e.g. 5 mg/kg once
weekly)
CIII [195, 201]
EBV
(meningoencephalitis)
Primary or salvage
treatment
- to cure -
Reduction of immunosuppression AIII Might not always be possible [188, 202]
Ganciclovir (i.v., 5 mg/kg q12h) BIII Valganciclovir (orally) has also been used [202–207]
Aciclovir (i.v., 10 mg/kg q8h) CIII Few reports with success published [208, 209]
HHV-6 Primary or salvage
treatment
- to cure -
Foscarnet (i.v., 60 mg/kg q8h or 90 mg/kg
q12h) or ganciclovir (i.v., 5 mg/kg q12h)
AIII Variant A and B might respond similarly to antivirals [7, 77, 78, 210–213]
Foscarnet (i.v., 60 mg/kg q8h or 90 mg/kg
q12h) + ganciclovir (i.v., 5 mg/kg q12h)
CIII [78, 214]
Cidofovir (i.v., e.g. 5 mg/kg once weekly) CIII [215]
VZV Primary or salvage
treatment
- to cure -
Aciclovir (i.v., 10 mg/kg q8h)f AIII Inefficacy has been reported [2, 73, 216–218]
Aciclovir (i.v., 10 mg/kg q8h) + foscarnet
(i.v., 60 mg/kg q8h or 90 mg/kg q12h)
CIII [219]
Ganciclovir (i.v., 5 mg/kg q12h) CIII [188, 220]
JC virus (PML) Primary or salvage
treatment
- to cure -
Reduction of immunosuppression AIII Not always possible [12]
Cidofovir DIIt,u [221]
Bacteria To reduce mortality Empiric treatment AIIt,u [107, 222, 223]
To reduce mortality
and neurologic
defects
Dexamethasone (e.g. 0.15 mg/kg q6h for the
first 4 days)
CIIr,t Should be started with first dose of antibiotics if it is used [224, 225]
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Due to the lack of systematic data, decisions about the dur-
ation of antimicrobial treatment should be assessed individually.
Hereby, the strategy of treatment (such as antimicrobial drug
therapy with or without surgery), resolution of symptoms and
recovery of the individual immune-status, as defined by the
presence of neutropenia, hypogammaglobulinemia and graft-
versus-host disease should be taken in account. In patients with
persisting complex immunodeficiencies, targeted antimicrobial
treatment might be followed by maintenance treatment (e.g. for
cerebral toxoplasmosis). To improve efficacy and minimize tox-
icity, therapeutic drug monitoring (TDM) might be useful for
antimicrobial agents, such as 5-fluorocytosine (5-FC), voricon-
azole and posaconazole [BII] [229, 230]. TDM might be of par-
ticular relevance in patients with hematological disorders since
impaired gastrointestinal resorption and interferences with
co-medication are common in this population [230–232].
adjunctive treatment
Adjunctive treatment may include neurosurgery, platelet trans-
fusion and administration of corticosteroids, anticonvulsants,
sedatives or antipyretics (see supplementary Material, available
at Annals of Oncology online).
CNS infections related to specific
causative agents
parasitic CNS infections
Toxoplasma spp. belong to the most common causative agents
in allo-HSCT recipients with CNS infections [1, 6]. However,
other parasitic CNS infections such as malaria, microsporidio-
sis, leishmaniasis, trypanosomiasis or helminthic infections
have also been described in immunocompromised hosts [233].
Toxoplasma spp. Mental abnormalities, fatigue and fever are
frequent clinical symptoms in allo-HSCT recipients with cerebral
toxoplasmosis [234]. Neuroimaging by MRI frequently shows
typical hypo-/isointensities mainly in the basal ganglia and the
frontal lobe (supplementary Figure S1, available at Annals of
Oncology online) [105]. Higher sensitivity of MRI compared with
CT scan has been demonstrated in a comparative retrospective
analysis [104, 105]. However, typical nodular or ring enhancement
surrounded by edema was visible by MRI in only 60% of allo-
HSCT patients [235]. Besides neuroimaging, diagnosis of cerebral
toxoplasmosis is based on demonstration of tachyzoites or cysts in
the CSF [A], CSF PCR [B] and serological tests such as CSF
enzyme-linked immunosorbent assay [C] [24, 25, 29].
Primary treatment of cerebral toxoplasmosis should comprise
a combination of pyrimethamine and sulfadiazine [AIIt] [110].
Pyrimethamine in combination with clindamycin [BIIt] or
single-agent trimethoprim-sulfamethoxazole [BIIt] may alter-
natively be used [110, 111, 236]. Maintenance treatment should
be conducted for at least 3 months [BIII]. Atovaquone could be
administered in patients with intolerance/refractoriness to
conventional antitoxoplasmic agents [BIIt,u] [115, 116].
fungi
The predominant fungal pathogens causing CNS infections in
patients with hematological disorders are Aspergillus spp., with
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A. fumigatus prevailing over other species such as A. nidulans,
A. terreus and A. flavus [117]. Mucorales, C. neoformans and
Candida spp. may also be detected in these patients [150].
Aspergillus spp. Most commonly, CNS Aspergillosis results in
brain abscess formation, but fungal embolism can also cause
cerebral infarction with or without hemorrhage. Rarely, CNS
aspergillosis presents with overt meningitis or cause granuloma
[32, 150, 237].
MRI may show ring-enhanced lesions, infarction and dural or
vascular infiltration from adjacent regions (supplementary
Figure S2, available at Annals of Oncology online) [238, 239]. A
definitive diagnosis frequently requires biopsy of suspicious
lesions and demonstration of typical septate hyphae [A] [30,
31]. Several studies indicate that detection of CSF galactoman-
nan [B] or the PCR assay [B] might also be useful to diagnose
CNS aspergillosis [32–35, 37]. In Aspergillus meningitis, CSF
galactomannan might be detected in almost 90% of cases,
whereas fungal cultures are positive in ∼30% [32]. CSF fungal
cultures are usually negative in patients with Aspergillus CNS in-
fection other than meningitis [32].
Voriconazole is the drug of choice in CNS aspergillosis, as this
azole displays sufficient penetration into the CNS [AIIu] [117,
118, 240]. Amphotericin B deoxycholate (D-AmB) should be
avoided due to its poor tolerability and negligible efficacy [DIIu],
but the use of higher doses of liposomal AmB (L-AmB) resulted
in successful outcomes in a limited number of patients [BIII]
[119–123, 134]. Due to its limited CNS penetration and the
limited number of successfully treated cases in the literature, the
use of itraconazole does not appear justifiable in patients with
CNS aspergillosis [DIII] [127–129]. Posaconazole has been used
in a series of patients with CNS infections caused by various
fungi, including three assessable patients with CNS aspergillosis
[DIII] [132]. Caspofungin has demonstrated some activity in a
mouse model exploring CNS aspergillosis, but clinical data on the
use of echinocandins in CNS aspergillosis are scarce [130, 131].
Some animal model data suggest that combination therapy (e.g.
voriconazole with L-AmB) might be beneficial, but meaningful
clinical data are not available to recommend the use of combin-
ation therapies in CNS aspergillosis [DIII] [241, 242].
Intrathecal or intralesional administration of AmB has been
repeatedly been applied to patients with CNS aspergillosis, but
published data are limited to case reports [DIII] [243, 244]. In
addition, intrathecal D-AmB could cause chemical arachnoiditis
and it is unlikely that sufficient drug concentration is achieved
in infected brain tissues [245]. Adjunctive corticosteroid therapy
could reduce mass effects and brain edema, but should be
avoided whenever possible due to its deleterious effects in inva-
sive fungal infections [246]. If corticosteroid therapy is unavoid-
able, prednisolone should be preferred over dexamethasone, as
dexamethasone is associated with low voriconazole levels
(S. Schwartz, personal communication).
Neurosurgical interventions could facilitate diagnostic con-
firmation and contribute to a successful outcome, likely by
removing infarcted areas with poor drug penetration [BIIu]
[117, 118, 136, 137].
Candida spp.. Candida CNS infections typically present as
meningoencephalitis or as ventriculitis associated with foreign
bodies such as shunts or, rarely, as brain abscesses. Candida
microabscesses could be discovered at autopsy, while CT and
CSF analysis not always show clearly pathological findings in
this situation [44]. Neuroimaging might show hydrocephalus in
Candida meningitis and MRI is considered to be more sensitive
than CT scan [44, 147]. In the case of Candida meningitis,
yeasts can be detected by CSF staining in ∼40% and in ∼40%–
80% by fungal cultures [A] [44, 45]. The PCR technique as well
as the detection of (1→ 3)-β-D-Glucan or the Candida mannan
antigen might also be useful to diagnose Candida meningitis
from CSF, but these methods are not yet considered as clinical
routine procedures [C] [38, 46, 47, 49].
Most data on the treatment of Candida CNS infection are
derived from pediatric patients. The use of D-AmB with 5-FC
has been suggested as the optimal initial therapy for many years
due to the excellent CSF penetration of 5-FC, the documented
synergism of both compounds in vitro and in vivo and their
documented clinical activity in Candida infections [44, 150].
The rationale for the use of L-AmB is mainly reasoned by
studies in experimental Candida meningoencephalitis and
clinical data from preterm newborns [140, 141, 247, 248]. Since
L-AmB has an improved toxicity profile compared with
D-AmB, the combination of L-AmB and 5-FC should be pre-
ferred to treat Candida CNS infections [BIII]. Fluconazole,
alone or in combination with 5-FC, may be used as an oral con-
solidation therapy [BIII]. Voriconazole is a reasonable thera-
peutic option for Candida CNS infection [CIII] [145, 249].
Animal models suggest the potential usefulness of the echino-
candins in Candida CNS infection, although higher doses might
be required (as studied for micafungin) [151]. Clinical data are
limited to case reports; thus this approach cannot be recom-
mended for routine use yet [DIII] [152]. Any indwelling device
such as a ventricular drain or a central venous line should be
removed in invasive Candida infection [BIII] [250, 251].
mucorales. Mucormycosis is a rare opportunistic infection
mainly caused by Rhizopus spp. and Mucor spp. [9, 156]. The
brain might be involved in a disseminated infection or by
infiltration from adjacent rhino-sinu-orbital regions [8–10, 154,
156]. Clinical symptoms such as facial pain or swelling may
be nonspecific but are frequently present in patients with
rhinocerebral mucormycosis [158]. The CT scan frequently
reveals characteristic bone destruction of the paranasal sinuses,
the hard palate or adjacent structures [252]. The diagnosis should
always be confirmed by a histopathological examination and/or
culturing of tissue specimens [A]. Histopathological examination
of infected tissue typically shows the irregular fungal hyphae
with wide-angle branching, in addition to tissue necrosis and
fungal angioinvasion [53]. PCR assays using infected tissue
specimens [B] or blood [C] have also been evaluated to diagnose
mycormycosis [54, 55, 57]. However, these methods are not
standardized yet.
Single-agent L-AmB is recommended to treat mucormycosis
[AIIt,u], but some experts suggest a primary polyene–caspofun-
gin combination [CIII] [158–160]. Immediate surgical resection
of necrotic tissue may be crucial in addition to antifungal treat-
ment in invasive mucormycosis [AIIt,u] [8, 9, 154, 155]. Besides
reduction of immunosuppressive drugs conditions associated
with the occurrence of mucormycosis such as hyperglycemia,
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lactic acidosis and iron overload should be corrected whenever
possible [BIII]. However, a placebo-controlled trial exploring
L-AmB together with the iron chelating agent deferasirox was
terminated prematurely due to inefficacy, despite the crucial role
of iron in the pathogenesis of mucormycosis [DIIt] [253].
Posaconazole [BIII] or isavuconazole [CIII] might be used
as salvage treatment of mucormycosis [167–170]. Hyperbaric
oxygen has been investigated as primary or salvage treatment of
mucormycosis [254–256]. This approach is available only in
some centers and there are no larger trials confirming its benefit
[CIII].
Cryptococcus spp. Reports from human immunodeficiency
virus (HIV)-negative patients with hematological disorders and
infection with Cryptococcus spp. are limited [257, 258].
Neuroimaging by MRI may show dilated Virchow-Robin spaces,
cyst-like structures and granuloma of the choroid plexus [259].
A definitive diagnosis of cryptococcal meningitis is made by
CSF cultures [A] or CSF microscopy using India Ink staining
[A] [58–60, 62]. The diagnosis might further be confirmed by
detection of capsular antigen using different techniques such as
enzyme immune assays, latex agglutination or the lateral flow
assay [A] [58, 61]. Likewise, CSF (nested) PCR assays might be
used to diagnose cryptococcal meningitis [B] [58, 61]. Biopsy of
infected tissues followed by culturing and histopathological
investigation is required only in selected cases [C] [60].
Primary treatment of cryptococcal meningitis should encom-
pass a combination of L-AmB and 5-FC [AIIt] [171, 172, 181,
260]. Voriconazole or posaconazole may be used for salvage
treatment [CIII] [132, 180, 183]. Cryptococcus spp. are in vitro
resistant to echinocandines [184]. Thus, these agents do not
play a role in the treatment of cryptococcal meningitis [DIII].
Reducing the CSF opening pressure (e.g. by repetitive lumbar
punctures) is useful besides anti-infectious drug therapy in
selected patients with cryptococcal meningitis [BII] [172, 261].
viruses
Herpes viruses, in particular herpes simplex virus (HSV),
Epstein–Barr virus (EBV) and human herpes virus-6 (HHV-6)
are prevailing in allo-HSCT recipients [2, 73]. Viral CNS infec-
tions typically present as meningoencephalitis, but strokes—e.g.
caused by varicella zoster virus (VZV)—or leukoencephalopathy
(e.g. JC virus-associated PML) might occur [18]. The diagnosis
of viral CNS infections is usually made by CSF PCR together
with neuroimaging, preferably MRI [2, 109, 262].
CSF viral PCR assays have an excellent sensitivity and specifi-
city of 90%–100% for the majority of virus types [64, 65]. Thus,
CSF PCR is regarded as a ‘gold standard’ for diagnosis of viral
CNS infections [A]. However, studies comparing viral isolation
from autopsy samples or brain-biopsy specimens—the former
reference standard—with PCR are available only for few viruses
such as HSV or cytomegalovirus (CMV) [64, 65, 70]. CSF virus
PCR might initially be false-negative and the probability of a
positive PCR increases when there is a time frame of 3–14 days
between onset of symptoms and lumbar puncture [263].
herpes simplex virus. The incidence of HSV encephalitis is
relatively low in patients with hematological disorders and there
have been few cases published which mainly include allo-HSCT
recipients [2, 73, 264].
CSF PCR is a rapid method to diagnose HSV encephalitis
with high sensitivity and specificity (both >90%) [A] [64, 65].
Detection of CSF HSV antibodies is not a reliable diagnostic
tool for HSV encephalitis since the sensitivity and specificity is
only 75%–85% and 60%–90%, respectively [C] [66]. Detection
of CSF HSV antigen has a sensitivity and a specificity of ∼90%
and might be of value as an adjunctive test [C] [66, 67]. CSF
viral cultures are frequently negative in HSV encephalitis [D]
[68]. Cerebral MRI typically shows abnormalities in the medial
and inferior temporal lobe, the insula and the cingulate (supple-
mentary Figure S3, available at Annals of Oncology online)
[265]. However, cerebral MRI might also be inconspicuous in
allo-HSCT recipients with HSV encephalitis [2, 73].
HSV encephalitis should immediately be treated with aciclo-
vir [AIIt] [73, 185–187].
In rare cases of aciclovir resistance, foscarnet may be adminis-
tered [CIII] [190]. Patients with HSV encephalitis have a good
overall prognosis, but a large proportion of patients (up to 70%)
recover with neurological sequelae [2, 187].
cytomegalovirus. CMV CNS disease is typically characterized by
ventriculo-encephalitis, retinitis and polyradiculopathy [195, 266,
267]. CSF CMV PCR has a high sensitivity (up to 100%) for the
diagnosis of CMV CNS disease [A] [69–72]. Detection of CMV
in CSF by viral cultures might only be used as an adjunctive test
since it has a low sensitivity of ∼20% [C] [69, 72].
CMV CNS disease is commonly treated with ganciclovir or
foscarnet [AIII] [188]. Some authors recommend a combin-
ation of both agents [BIII] [188, 195–197]. Cidofovir as single
agent or in combination with foscarnet or ganciclovir might be
used for salvage treatment [CIII] [195, 200, 201]. Some reports
support the use of leflunomide to control CMV disease [CIII]
[201, 268, 269]. There are no systematic data showing a benefit
of the routine administration of CMV hyperimmunoglobulin in
patients with hematological disorders and CMV disease.
Epstein–Barr virus. Except for patients with allo-HSCT, EBV
disease other than infectious mononucleosis is a rare entity.
Diagnosis of EBVmeningoencephalitis is based on CSF PCR [A] [2,
73–75]. However, brain-biopsy-proven EBV meningoencephalitis in
conjunction with a negative CSF EBV PCR has been reported [76].
A reduction of immunosuppression should be attempted
whenever possible in patients with EBV disease or infection
[AIII] [188]. The role of rituximab in EBV disease (i.e. presence
of EBV organ involvement) remains to be elucidated despite the
fact that first experiences suggest that pre-emptive treatment of
EBV infections (i.e. EBV reactivation only) might reduce the in-
cidence of post-transplant lymphoproliferative disorder [270].
Likewise, it remains unclear whether antivirals are beneficial in
EBV disease [188]. Ganciclovir, valganciclovir or foscarnet
might be used to treat EBV meningoencephalitis [BIII] and
there are few case reports on the potential efficacy of aciclovir in
this situation [CIII] [188, 202–209].
human herpes virus-6. HHV-6 CNS disease (mainly
encephalitis) has rarely been described except in allo-HSCT
recipients [2, 7, 77, 78, 210]. HHV-6 encephalitis typically
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affects allo-HSCT recipients with unrelated (mainly cord blood)
donors and it frequently develops at the time of engraftment (or
shortly thereafter) [2, 7]. Common clinical symptoms include
alteration of consciousness, short-term memory loss and
seizures [2, 7, 271]. The diagnostic method of choice for
diagnosis of HHV-6 meningoencephalitis is quantitative CSF
PCR [A] [77, 78]. However, it should be noted that HHV-6
DNA might be detected in CSF in a significant proportion of
asymptomatic allo-HSCT recipients [79]. CSF analysis might
show elevated protein levels and, more rarely pleocytosis [2, 77].
Imaging abnormalities which typically involve the temporal
lobe are more likely visible in MRI than in CT scan
(supplementary Figure S4, available at Annals of Oncology
online) [2, 77]. Despite this, cerebral MRI might be normal in
the early phase of HHV-6 meningoencephalitis in allo-HSCT
recipients [2, 77, 78].
Ganciclovir or foscarnet could be used as first-line therapy for
HHV-6 meningoencephalitis [AIII] [7, 8, 210–213]. Cidofovir
can be administered as second-line treatment [CIII] [215].
varicella zoster virus. Primary VZV infection (chickenpox)
occurs rarely in patients with hematological disorders, since
VZV-seronegativity in adulthood is rare (∼5%). In VZV-
seropositive recipients, VZV disease after allo-HSCT most
commonly manifests as dermatomal herpes zoster but a VZV
meningoencephalitis may occur [2, 216, 217]. Small patient
series indicate that CSF PCR has a similar good sensitivity and
specificity for diagnosis of VZV meningoencephalitis as for
other herpes viruses [A] [80–82]. The CSF VZV viral load
determined by PCR might correlate with the severity and the
duration of VZV meningoencephalitis [218]. Diagnosis of VZV
meningoencephalitis may be confirmed by serological tests such
as detection of intrathecal VZV glycoprotein E [272]. Rash and
CSF pleocytosis might be absent in patients with cerebral VZV
vasculopathy (such as strokes). In this situation, detection of
CSF anti-VZV IgG antibodies might have a higher sensitivity
than CSF VZV PCR [B] [83].
VZV CNS infections can be successfully treated with aciclovir
[AIII] [2, 73, 218]. However, aciclovir resistance could occur
and there are case reports on fatal CNS meningoencephalitis in
allo-HSCT recipients despite early therapy with high-dose acic-
lovir [216]. These patients might benefit from a combination of
aciclovir and foscarnet [CIII] [219].
JC virus. JC virus-related PML typically affects severely
immunocompromised hosts such as Acquired Immune
Deficiency Syndrome (AIDS) patients or allo-HSCT recipients
[2, 273]. CNS biopsy of suspicious lesions is required for
definitive diagnosis of PML [A]. The typical triad
(demyelination, bizarre astrocytes and enlarged oligodendroglial
nuclei) can frequently be demonstrated by histopathological
work-up in biopsies which might be combined with tissue and
CSF JC virus (dual qualitative-quantitative nested) PCR [A] [86,
88, 89]. MRI typically shows abnormalities in the posterior
white matter without contrast enhancement (supplementary
Figure S5, available at Annals of Oncology online) [274]. The
diagnosis of PML could also be established without CNS biopsy
in immunocompromised patients with typical clinical symptoms
and characteristic findings by neuroimaging together with a
positive CSF JC virus PCR [A] [86].
Immune reconstitution seems to be crucial for treatment of
PML, as suggested by the observation that the incidence of PML
could be markedly reduced in AIDS patients by the introduction
of highly active antiretroviral therapy (HAART) [273, 275].
However, PML might develop or worsen (in the case of pre-
existing PML) at the beginning of HAART (PML-immune re-
constitution inflammatory syndrome, IRIS) [273, 275, 276].
PML-IRIS has also been described during withdrawal of agents
which are associated with the occurrence of PML, such as
natalizumab [277].
Immunosuppressives should be reduced in allo-HSCT recipi-
ents with PML whenever possible [AIII] [12]. Treatment with
cidofovir may be beneficial in some patients with PML [2, 278,
279]. In contrast, other allo-HSCT recipients as well as a larger
series of 370 AIDS patients with PML did not improve after
treatment with cidofovir [DIIt,u] [12, 221]. Several experimental
approaches such as adoptive T-cell therapy or administration of
interleukin-2, mefloquine or mirtazapine have been tested as a
treatment option for PML [12, 278–280]. Since none of them
has clearly shown to be effective in larger series of patients they
are recommended within experimental protocols only [DIII].
conclusions
Diagnosis of CNS infections remains a great challenge in
patients with hematological disorders since symptoms might
both be masked and be mimicked by other conditions such as
metabolic disturbances or consequences from antineoplastic
treatment. Thus, awareness of this complication is crucial and
any suspicion of a CNS infection should lead to timely and ad-
equate diagnostics and treatment to improve the outcome in
this population.
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